IP Library Granted Patent US 9,889,235
Granted Patent B2
US 9,889,235 · App. 14/765,662 · Granted Feb 13, 2018

Implantable devices for bone or joint defects

Inventors: Amanda Brooks (South Jordan, UT); David Grainger (Salt Lake City, UT); Kristofer D. Sinclair (Salt Lake City, UT); Benjamin Brooks (South Jordan, UT)
Assignee: University of Utah Research Foundation
A61L27/58A61K31/7036A61L27/26A61L27/306A61L27/3608A61L27/54B05D3/002B29C67/24A61L2300/406A61L2300/412A61L2300/62A61L2430/02A61L2430/24B05D2203/00B29K2001/08B29L2031/7532
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,889,235
App. No.
14/765,662
Granted
Feb 13, 2018
Kind
B2
Abstract

In one aspect, the invention provides an implantable device comprising a uniform mixture of components including degradable polymer, inorganic bone particulate either natural or synthetic, a drug, and a soluble microporagen. In some embodiments, the uniform mixture further includes a soluble polymer macroporagen. In some embodiments, the uniform mixture is coated with an immobilized outer porous layer comprising or consisting of synthetic or natural inorganic bone granules. In further aspects, the invention provides an implantable device comprising a composite core of degradable polymer, bone, and a drug, and a coating comprising or consisting of microporous bone overlayer covering the degradable composite core.

Claims (34)

1. An implantable device comprising a uniform mixture of components including:

degradable polymer comprising a composition selected from the group consisting of polycaprolactone, poly(lactic-co-glycolic) acid, and mixtures thereof,

bone,

a drug,

a macroporagen including polyethylene glycol, and

a microporagen selected from the group consisting of CaCl 2 , MgCl 2 , and MgCO 3 , wherein:

(a) the amount of bone by weight exceeds the combined weight of all the other components,

(b) the components are selected and provided in relative amounts such that following implantation;

(i) water molecules dissolve the microporagen to create micropores in the device,

(ii) the water molecules enter the resulting micropores,

(iii) the entering water molecules dissolve or degrade the macroporagen and the degradable polymer,

(iv) the drug is released while creating sufficient space for cell migration into the device and while retaining structural integrity of the device long enough to serve as a scaffold to establish osteoconduction, and

(c) the degradable polymer has a degree of crystallinity and molecular weight which render the device resorbable and able to release the drug over a time period of at least six weeks following implantation.

2. The device of claim 1 , wherein the bone is synthetic bone.

3. The device of claim 1 , wherein the macroporagen further includes a composition selected from the group consisting of alginate, polyvinylpyrrolidone, NaCMC, hydroxypropylcelluose, hyaluronic acid, and combinations of the foregoing.

4. The device of claim 1 , further comprising a coating covering the uniform mixture.

5. The device of claim 4 , wherein the coating comprises bone.

6. The device of claim 1 , wherein the drug is microencapsulated.

7. The device of claim 1 , wherein the amount of degradable polymer by weight exceeds the amount of macroporagen by weight, and the amount of macroporagen by weight exceeds the amount of microporagen by weight.

8. A method for treating and/or preventing infection at a site of implantation in a patient in need of a bone or joint replacement, comprising implanting the device of claim 1 into the site of implantation.

9. A method for manufacturing the device of claim 1 comprising:

a) combining

the degradable polymer comprising a composition

selected from the group consisting of polycaprolactone poly(lactic-co-glycolic) acid and mixtures thereof,

the drug,

the bone,

the macroporagen including polyethylene glycol, and the microporagen selected from the group consisting of CaCl 2 , MgCl 2 , and MgCO 3 over heat to make a uniform mixture by increasing the mixture temperature;

b) dispensing the heated uniform mixture into a mold of a pre-determined shape and size according to an anatomical need;

c) cooling the uniform mixture to a temperature at which the uniform mixture will harden in the mold; and

d) releasing the hardened uniform mixture from the mold to produce the device.

10. The method of claim 9 , wherein the method further comprises

e) contacting the surface of the implantable device produced by step (d) with morselized bone, and

f) allowing the morselized bone to embed into the surface of the device to form a coating of bone on the device using mechanical force, ultrasonic energy or locally applied heat.

11. The method of claim 9 , wherein the uniform mixture is a composite.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2015
From: BROOKS, AMANDA; GRANGER, DAVID; SINCLAIR, KRISTOFER D.; BROOKS, BENJAMIN
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 036393/0119 →
Continuity (2)
Provisional Application 61761086 · Feb 5, 2013
Related Publication 20160129157A1 · May 12, 2016